KALA BIO, INC. Long-term Line of Credit
KALA BIO, INC. (KALA) had Long-term Line of Credit of $450.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Balance Sheet › Liabilities › Debt
us-gaap:LineOfCredit · last filed 2023-08-04
- 2022-12-31: Long-term Line of Credit $450.00K.
- 2022-09-30: Long-term Line of Credit $450.00K.
- 2022-06-30: Long-term Line of Credit $450.00K.
- 2022-03-31: Long-term Line of Credit $450.00K.
| Period end | Long-term Line of Credit | Long-term Line of Credit as first filed |
|---|---|---|
| 2022-12-31 | $450.00K 10-K · filed 2023-03-03 | |
| 2022-09-30 | $450.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $450.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $450.00K 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $450.00K 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $450.00K 10-K · filed 2022-03-29 | |
| 2020-06-30 | $500.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $500.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $450.00K 10-Q · filed 2023-08-04 | $500.00K 10-K · filed 2020-02-12 |
| 2019-09-30 | $500.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $500.00K 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |